This medication has proven to be a game-changer, demonstrating a substantial reduction in the five-year risk of recurrent cancer by an impressive 73% ... Nov 14
This approval follows a priority review designation by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) and marks the first ... Jun 23
Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%... Dec 21
Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose ... Dec 19
Genprex receives conditional FDA acceptance of proprietary name REQORSA for lead drug candidate for the treatment of non-small cell lung cancer ... Oct 30
Option would extend dosing to four weeks in non-small cell lung and bladder cancer reducing medical visits by half ... Aug 20
AstraZeneca has already reached deals with countries to make more than 2 billion doses of its COVID-19 vaccine with Oxford Univeristy ... Jul 31
AstraZeneca comes up with ground breaking data on lungs cancer... Mar 02
-Advertisements-
.jpeg)
Friday, November 22, 2024
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)